| Name | Title | Contact Details |
|---|
Mitsui Bussan Logistics Inc is a Dallas, TX-based company in the Business Services sector.
G.F. Bowman Inc is a Cleona, PA-based company in the Business Services sector.
Adventure Recruitment is a Los Angeles, CA-based company in the Business Services sector.
TIXiMED, Inc. is focused on developing and commercializing TXNIP inhibiting medication as a first-of-its-kind oral therapeutic for Type 1 and Type 2 diabetes. TIXiMED is the exclusive license holder for the patent (composition of matter and method of use) surrounding TIX100, a novel small molecule that normalizes pancreatic beta cell TXNIP, a detrimental protein elevated in Type 1 and Type 2 diabetes. Increased TXNIP causes pancreatic islet dysfunction and death of insulin-producing beta cells and thereby contributes to the development and progression of diabetes. Diabetes affects more than half a billion people worldwide. Those affected by Type 1 diabetes are dependent on multiple daily insulin injections or continuous insulin infusions to stay alive and manage their blood sugar. Oral anti-diabetic drugs are only approved for Type 2 diabetes, but can be associated with multiple side effects, underlining the need for novel and better oral diabetes medications for Type 1 and Type 2 diabetes. TXNIP inhibition has recently been demonstrated to be an effective and safe therapeutic approach in adults and children with recent onset Type 1 diabetes and TIX100 shows beneficial, anti-diabetic effects in 4 different mouse models. Advantages of TIX100 include oral availability, no associated hypoglycemia or weight gain, potent inhibition of detrimental TXNIP in human islets, and a favorable pharmacokinetic and safety profile. In addition, TIX100 inhibits excessive glucagon secretion and hepatic glucose production and protects against fatty liver. Thus, TIX100 holds promise for durable, weight-neutral improvement in glycemic control in Type 1 and Type 2 diabetes by targeting common underlying pathology and promoting patients own islet cell health.
Title Alliance Ltd., specializes in the creation and management of RESPA compliant title joint ventures in the real estate industry. Since 1983 we have formed over 75 joint ventures in Pennsylvania, New Jersey, Delaware, Florida, Indiana, New York, Maryland, Virginia, Ohio, Arizona and Michigan. Forming and running a title company requires a lot of time and commitment. Working with Title Alliance allows our partners to focus on their core business. Through the partners` trust in Title Alliance; the joint ventures run smoothly and the partners receive ancillary income through the form of dividends. Title Alliance has been and continues to be the premier developer of RESPA compliant, title joint ventures. Title Alliance`s expertise allows them to offer complete support of the title agency, which isn`t something that most competitors can offer. Title Alliance prides themselves on creating RESPA compliant title joint ventures, which isn`t something that all providers can say. Title Alliance doesn`t take shortcuts. We do the right thing and we do it the right way. From initial capitalization to proper distributions; Title Alliance partners are confident knowing that their entities are compliant on every level.